TransVascular gains FDA go-ahead for dual lumen CrossPoint catheter:
This article was originally published in Clinica
TransVascular has gained FDA 510(k) approval to sell its CrossPoint TransAccess catheter, a dual lumen device designed to facilitate the placement and positioning of catheters within the peripheral vasculature. The product is intended to avoid the guidewire becoming trapped in the vessel wall as it crosses the blockage, by aiding its return to the true lumen of the vessel. It should allow a higher percentage of peripheral angioplasty and stenting procedures to be completed successfully, said the Menlo Park, California firm.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.